Sign up to save your podcasts
Or
Share ACCEL Lite: Featured ACCEL Interview With Eric L. Michelson and Brendan Everett
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACCEL Lite: Featured ACCEL Interview With Eric L. Michelson and Brendan Everett
In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
View all episodes
By American College of Cardiology
3.8
5858 ratings
In this interview, Eric L. Michelson and Brendan Everett discuss anti-inflammatory therapy with canakinumab and incident type 2 diabetes: a prespecified key secondary endpoint of CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).
More shows like ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
View all
Investing Insights
518 Listeners
NEJM This Week
321 Listeners
JAMA Clinical Reviews
504 Listeners
JACC This Week
167 Listeners
This Week in Cardiology
906 Listeners
JACC Specialty Journals
21 Listeners
Circulation on the Run
31 Listeners
Mayo Clinic Talks
298 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
138 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
ACC CardiaCast
39 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Cardionerds: A Cardiology Podcast
437 Listeners
Mayo Clinic Cardiovascular CME
32 Listeners